Pegylated interferon alfa-CCR5 antagonist combination HIV...

Details Pegylated interferon alfa-CCR5 antagonist combination HIV... Pegylated interferon alfa-CCR5 antagonist combination HIV...

2007-07-24

2007-07-24

Hui, San-ming (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S253010, C514S253100, C514S253110, C514S253090, C514S340000

Reexamination Certificate

active

10430370

ABSTRACT:
Methods for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b, in association with a therapeutically effective amount of a CCR5 antagonist or preferably further in association with a therapeutically effective amount of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amount of an anti-HIV-1 drug therapy, e.g., HAART are disclosed.

REFERENCES:
patent: 6177074 (2001-01-01), Glue et al.
patent: 6635646 (2003-10-01), Laughlin
patent: WO 97/42969 (1997-11-01), None
patent: WO 98/01425 (1998-01-01), None
patent: WO 98/06697 (1998-02-01), None
patent: WO 98/25617 (1998-06-01), None
patent: WO 98/48840 (1998-11-01), None
patent: WO 99/17773 (1999-04-01), None
patent: WO 00/00488 (2000-01-01), None
Carpenter, C., et al Report of the NIH Panel to Define Principles of Therapy of HIV Infection, Ann. Intern Med. (vol. 128, No. 12 (part 2) pp. 1057-1078(1998).
Fauci, A., et a., Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, Ann. Intern. Med. vol. 128(No. 12, Part 2) pp. 1079-1100 (1998).

Affiliated with

Also associated with

Rating

Pegylated interferon alfa-CCR5 antagonist combination HIV... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pegylated interferon alfa-CCR5 antagonist combination HIV..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pegylated interferon alfa-CCR5 antagonist combination HIV... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3739318